Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate the Placental Transfer of Dapirolizumab Pegol to the Infant(s) From Pregnant Study Participants With Active Systemic Lupus Erythematosus Who Are Administered Dapirolizumab Pegol

NCT07934472 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT07934472 Not yet recruiting Phase 1 25 participants (estimated) Started 2026

Follow this trial by email Email me the PDF

Get the NCT07934472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started November 2026. Interventional study, Phase 1, 25 participants (estimated). Lead sponsor UCB Biopharma SRL. Primary measures: Plasma concentration of DZP in the infants at birth; Plasma concentration of DZP in mothers at delivery and 1 more.

How it compares

267 similar trials: same condition (Lupus Erythematosus, Systemic) and phase

Enrollment

This trial
25
Middle half
12 to 48
Median
23
Trials with a value
267

Months from start to completion

This trial
34.5
Middle half
17 to 39.1
Median
28.9
Trials with a value
264

Sites

This trial
Not reported
Middle half
1 to 6
Median
1
Trials with a value
246
Posted results or a linked paper 25% 68 of 267 similar trials; this trial: no

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate the Placental Transfer of Dapirolizumab Pegol to the Infant(s) From Pregnant Study Participants With Active Systemic Lupus Erythematosus Who Are Administered Dapirolizumab Pegol
Official title
A Prospective, Open-Label, Single-Arm, Multicenter Pharmacokinetic Study Evaluating the Placental Transfer of Dapirolizumab Pegol to the Infant(s) From Pregnant Study Participants With Active Systemic Lupus Erythematosus Who Are Administered Dapirolizumab Pegol
Lead sponsor
UCB Biopharma SRL
Phase
Phase 1
Overall status
Not yet recruiting
Start date
November 15, 2026
Completion date
September 30, 2029
Enrollment
25 (estimated)
Sites
Not reported

Conditions

MeSH condition names; the registry's own terms follow.

Lupus Erythematosus, Systemic

Registry terms: systemic lupus erythematosus

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
Female
Minimum age
18 Years
Maximum age
45 Years
Healthy volunteers
No
Study type
Interventional
Lead sponsor
UCB Biopharma SRL

Arms

As registered; 1 arm.

Registered arms
Arm Type Interventions
Dapirolizumab pegol (DZP) Experimental Dapirolizumab pegol (DZP)
Show registry wording

Pregnant women will receive DZP by intravenous (iv) administration during 2nd and 3rd trimester and after delivery they may continue for up to 1 year (if not breastfeeding).

Primary endpoints

Registered primary outcome measures; 3 primary.

Registered primary endpoints
Measure Time frame
Plasma concentration of DZP in the infants at birth At Birth during this study
Show registry wording

Plasma concentration of DZP will be reported in infants at birth.

Plasma concentration of DZP in mothers at delivery At Delivery during this study
Show registry wording

Plasma concentration of DZP in mothers at delivery will be reported.

Ratio between plasma concentration of DZP between the infants and mother at birth/delivery Infants: At Birth; Mothers: At Delivery during this study
Show registry wording

Ratio of plasma concentration of DZP between the infants and mother at birth/delivery will be reported.

Lead sponsor's other trials

UCB Biopharma SRL, most recent start first.

Similar trials

Same condition (Lupus Erythematosus, Systemic) and phase, most recent start first.